^
Association details:
Biomarker:No biomarker
Cancer:Small Intestinal Carcinoma
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Systemic Therapy for Metastatic Disease....For patients for whom intensive therapy is not recommended...capecitabine with or without bevacizumab recommended as first-line therapy for these patients....FOLFOX , CAPEOX, or FOLFIRINOX may be given with or without bevacizumab as first-line therapy for advanced SBA.
Secondary therapy:
FOLFIRINOX; CAPOX; FOLFOX; capecitabine